tezacaftor,
VX-661,
VX-661,
Tezacaftor,
1152311-62-0,
VX661,
VX 661,
UNII-8RW88Y506K,
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide,
8RW88Y506K,
cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl]-,
AK172569,
C26H27F3N2O6,
Tezacaftor [USAN],
Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-(1-((2R)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl)-,
Tezacaftor (USAN/INN),
Tezacaftor (VX-661),
SCHEMBL322362,
VX 661;VX661;Tezacaftor,
CHEMBL3544914,
SCHEMBL10034144,
GTPL10199,
KS-00000SZM,
DTXSID40673070,
MJUVRTYWUMPBTR-MRXNPFEDSA-N,
BDBM281054,
1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-N-{1-[(2R)-2,3-DIHYDROXYPROPYL]-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)INDOL-5-YL}CYCLOPROPANE-1-CARBOXAMIDE,
AMX10192,
BCP07173,
EX-A1759,
MFCD23106064,
s7059,
US10022352, Compound 315,
ZINC68206930,
AKOS025290350,
CS-1078,
DB11712,
PB30512,
AS-35211,
BC600502,
HY-15448,
QC-11636,
SC-95542,
example 315 [US20090131492A1],
FT-0772351,
SW219937-1,
Y0430,
D11041,
Q-4067,
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-,
(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropane-1-carboxamide,
(R)-1 (2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide,
(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropane-1-carboxamide,
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-~{N}-[1-[(2~{R})-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide,
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-(1-((2R)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl)cyclopropanecarboxamide,
1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide,
1-(2,2-Difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide,
D0Z5HR,
ACN-041468,
CFTR correctors (cystic fibrosis), Vertex,
A2664,
A12519,
Cystic fibrosis transmembrane regulator corrector (cystic fibrosis), Vertex,
Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-(VX-661),